Indaptus Therapeutics, Inc. (INDP)
USD 0.91
(0.29%)
USD 0.91
(0.29%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.4 Million | -13.07 Million | -11.29 Million | -3.32 Million | -29.04 Million | -39.07 Million |
| Net Income | -15.42 Million | -14.32 Million | -7.71 Million | -3.58 Million | -47.59 Million | -43.54 Million |
| Depreciation & Amortization | 1284.00 | 1781.00 | 1403.00 | 852.00 | 854 Thousand | 859 Thousand |
| Deferred income taxes | -1.63 Million | - | -5.74 Million | 3.35 Million | 281 Thousand | - |
| Stock-based compensation | 2.96 Million | 2.95 Million | 1.51 Million | 139.96 Thousand | 124.36 Thousand | - |
| Change in working capital | -518.07 Thousand | -1.58 Million | -5.09 Million | 118.71 Thousand | 227 Thousand | -642 Thousand |
| Other non-cash items | 1.19 Million | -134.15 Thousand | 5.74 Million | -3.35 Million | 18.96 Million | 6.63 Million |
| Investing Cash Flow | 17.14 Million | -16.42 Million | 447.74 Thousand | - | -3.21 Million | -9.3 Million |
| Investments in PPE | -5.00 | -172.55 Thousand | -3854.00 | - | -921 Thousand | -9.59 Million |
| Acquisitions | - | 172.55 Thousand | 451.6 Thousand | - | - | - |
| Investment purchases | -6.85 Million | -29.59 Million | - | - | - | - |
| Sales/Maturities of investments | 24 Million | 13 Million | - | - | 576 Thousand | 298 Thousand |
| Other Investing Activities | 17.14 Thousand | 172.55 Thousand | 451.6 Thousand | - | -2.86 Million | - |
| Financing Cash Flow | - | - | 48.33 Million | 1.16 Million | 2.36 Million | 35.05 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 5 Million | 1.16 Million | 2.36 Million | 35.05 Million |
| Other Financing Activities | - | - | 43.33 Million | 1.16 Million | 250 Thousand | - |
| Accounts receivables | - | - | - | 3.38 Million | -747 Thousand | -1.86 Million |
| Accounts payables | -680.52 Thousand | -1.15 Million | -4.23 Million | 113.9 Thousand | 679 Thousand | 1.19 Million |
| Inventory | - | - | - | -3.38 Million | - | - |
| Other working capital | 162.44 Thousand | -425.59 Thousand | -854.15 Thousand | 4811.00 | 295 Thousand | 28 Thousand |
| Cash at beginning of period | 9.62 Million | 39.13 Million | 1.63 Million | 3.79 Million | 39.24 Million | 53.39 Million |
| Cash at end of period | 13.36 Million | 9.62 Million | 39.13 Million | 1.63 Million | 9.29 Million | 39.24 Million |
| Capital Expenditure | -5.00 | -172.55 Thousand | -3854.00 | - | -921 Thousand | -9.59 Million |
| Effect of forex changes on cash | - | - | - | - | 29.89 Million | - |
| Net cash flow / Change in cash | 3.73 Million | -29.5 Million | 37.49 Million | -2.16 Million | -29.95 Million | -14.14 Million |
| Free Cash Flow | -13.4 Million | -13.25 Million | -11.29 Million | -3.32 Million | -29.96 Million | -48.67 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.01 Million | -3.8 Million | -15.42 Million | -4 Million | -3.92 Million | -3.24 Million |
| Depreciation & Amortization | - | 735.00 | 1284.00 | 320.00 | 321.00 | 322.00 |
| Deferred income taxes | - | - | -1.63 Million | 1.05 Million | - | 567.26 Thousand |
| Stock-based compensation | 782.85 Thousand | 774.69 Thousand | 2.96 Million | 745.52 Thousand | 764.8 Thousand | 728.46 Thousand |
| Change in working capital | 755.69 Thousand | -905.21 Thousand | -518.07 Thousand | 636.18 Thousand | -436.55 Thousand | 570.71 Thousand |
| Other non-cash items | 437.24 Thousand | 2.01 Million | 1.19 Million | -1.03 Million | -140.56 Thousand | -728.46 Thousand |
| Investing Cash Flow | - | - | 17.14 Million | -61.08 Thousand | 7 Million | 8 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -6.85 Million | 24.44 Thousand | 106.02 Thousand | 110.22 Thousand |
| Sales/Maturities of investments | - | - | 24 Million | -85.52 Thousand | 7 Million | 8 Million |
| Other Investing Activities | - | - | 17.14 Thousand | 61.08 Thousand | -106.02 Thousand | -110.22 Thousand |
| Financing Cash Flow | 35.16 Thousand | 316.04 Thousand | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 35.16 Thousand | 316.04 Thousand | - | - | - | - |
| Other Financing Activities | -1480.00 | -19.99 Thousand | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 396.94 Thousand | -1.23 Million | -680.52 Thousand | 397.81 Thousand | 261.43 Thousand | 280 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 358.75 Thousand | 332.28 Thousand | 162.44 Thousand | 238.36 Thousand | -697.99 Thousand | 290.71 Thousand |
| Cash at beginning of period | 9.74 Million | 13.36 Million | 9.62 Million | 15.96 Million | 12.69 Million | 6.8 Million |
| Cash at end of period | 7.3 Million | 9.74 Million | 13.36 Million | 13.36 Million | 15.96 Million | 12.69 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -2.43 Million | -3.62 Million | 3.73 Million | -2.6 Million | 3.26 Million | 5.89 Million |
| Free Cash Flow | -2.42 Million | -3.93 Million | -13.4 Million | -2.6 Million | -3.73 Million | -2.1 Million |
VALIANTLAB
DEF
NCX
FUU
PRIZ
0ROG